We are investors in Noveome Biotherapeutics, a company advancing a novel secretome-based therapeutic, which was developed and will be manufactured in Pittsburgh.  We believe that Pittsburgh’s scientific community, with ties to world-class medical institutions, will be integral to the company’s success.

Michael Kaufman

Chief Investment Officer and Managing Member of MAK Capital